TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Changing Agendas on Sleep, Treatment and Learning in Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Children diagnosed with RE (see International League Against Epilepsy Diagnostic Manual at https://www.epilepsydiagnosis.org/syndrome/ects-overview.html)~2. EEG showing focal sharp waves with normal background (see International League Against Epilepsy Diagnostic Manual at https://www.epilepsydiagnosis.org/syndrome/ects-eeg.html)~3. Aged ≥5 years and \<13 years at the time of randomisation~4. Currently untreated with antiepileptic drugs~5. Written informed consent received from person with parental responsibility/legal representative.~6. Family have an email address and regular internet access (for online sleep intervention)~7. Parent and child are to have a good understanding of the English language~Exclusion Criteria:~1. Known contraindication to any of the trial drugs~2. Previously treated for epilepsy with antiepileptic drugs

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Carbamazepine plus sleep intervention (Type: ACTIVE_COMPARATOR): None
- Carbamazepine plus standard care (Type: ACTIVE_COMPARATOR): None
- Levetiracetam plus sleep intervention (Type: ACTIVE_COMPARATOR): None
- Levetiracetam plus standard care (Type: ACTIVE_COMPARATOR): None
- No AED plus sleep intervention (Type: ACTIVE_COMPARATOR): None
- No AED plus standard care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Waldenström's Macroglobulinemia using criteria proposed at 2nd International Workshop on WM, Athens, Greece, 2002.~* Measurable disease, defined as serum monoclonal IgM protein ≥1000 mg/dL by electrophoresis.~* Lymphoplasmacytic infiltration of the bone marrow \>10% involvement.~* Failed at least one, but no more than 3, regimen(s) of prior therapy.~(Please consult with study site for full eligibility criteria)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females with histologically confirmed metastatic clear cell RCC~* Measurable disease according to Response Criteria for Solid Tumors (RECIST)~* No prior systemic cytotoxic chemotherapy~* Subjects who have received either no prior therapy for RCC, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting VEGF or a VEGFR (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled~* ECOG performance status of 0 or 1~* Life expectancy ≥3 months~* Adequate organ and marrow function~* No other malignancies within 5 years~* Signed informed consent~Exclusion Criteria:~* Radiation to ≥25% of bone marrow within 30 days of XL999 treatment~* Subjects who have received systemic anticancer therapy within 30 days of XL999 treatment~* Subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered \>30 days prior to study enrollment~* History of or known brain metastases, current spinal cord compression or carcinomatous meningitis~* Uncontrolled and/or intercurrent illness~* Pregnant or breastfeeding females~* Known HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject has a diagnosis of Pompe disease based on documented deficiency of GAA activity and a documented GAA mutation.~2. Male and female subjects between 18 years and 75 years, inclusive and ≥ 50 kg.~3. Subject must be currently receiving standard-of-care ERT (alglucosidase alfa) at a dose of 20 mg/kg dose every other week.~4. Subject must have been on ERT for the preceding 2 years or more.~5. Subject must have an upright forced vital capacity (FVC) within 35 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6 minute walk distance (6MWD) is \> 200 m. Subject must have an upright FVC within 40 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6MWD is ≤ 200 m. If FVC is between 80 and 90% of predicted normal, the subject may enter the study if the percent predicted FVC value drops by 10% predicted or more in supine position~6. Subject is able to walk at least 100 m in the 6MWT and the assessment is noted as valid.~Exclusion Criteria:~1. Subject has received any investigational therapy or pharmacological treatment for Pompe disease, other than alglucosidase alfa within 30 days or 5 half lives, whichever is shorter, prior to the Baseline Visit or is anticipated to do so during the course of the study~2. Subject is on any of the following prohibited medications within 30 days of baseline:~   * miglitol (eg, Glyset)~  * miglustat (eg, Zavesca)~  * acarbose (eg, Precose, Glucobay)~  * voglibose (eg, Volix, Vocarb, Volibo)~3. Subject requires use of invasive or non-invasive ventilatory support for \> 6 hours a day while awake.~4. Subject has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms.~5. Subject is breastfeeding, or is pregnant or planning to become pregnant within the next 2 years.~6. Other exclusion criteria according to the Lumizyme/Myozyme instructions for use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Family Planning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Intend to deliver in the Labor and Delivery Unit at Ohio State University Wexner Medical Center, Grady Memorial Hospital or Emory University Midtown;~2. Are ≥18 years of age;~3. Speak English;~4. Intend to breastfeed, or express milk for their infant, for ≥6 months;~5. Do not want to become pregnant within the first 12 months after delivery;~6. Want to start use of DMPA immediately after delivery before discharge or no hormonal contraception immediately postpartum; AND~7. Intend to reside in Ohio or Georgia for the first 12 months after delivery.~   Exclusion Criteria:~8. Undiagnosed vaginal bleeding;~9. Known or suspected malignancy of breast;~10. Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease;~11. Liver dysfunction or disease; OR~12. Known hypersensitivity to Depo-Provera.~Women who enroll prenatally will need to rescreen following delivery to confirm their eligibility. Women enrolling after delivery or who are rescreening will need to meet criteria 2-12 above as well as the following eligibility criteria:~1. Are a postpartum patient in the Labor and Delivery Unit at OSUWMC, Grady Memorial Hospital or Emory University Midtown Hospital; AND~2. Have delivered a term, singleton infant of ≥2500 grams without any apparent health concerns.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
- Placebo arm (Type: PLACEBO_COMPARATOR): 0.9% sodium chloride injection provided within 48 hours of childbirth
- Open arm (Type: NO_INTERVENTION): No intervention provided

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient Satisfaction and Postoperative Analgesia Between Subarachnoid Block With 2-chloroprocaine Versus General Anesthesia for Knee Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ASA physical status classification of I, II, or III~* Patients without a current diagnosis of chronic pain or chronic opioid use for \> 1-month prior to knee arthroscopy~* Patients who are scheduled to undergo unilateral knee arthroscopy~* Patients do not have a contraindication to receiving regional anesthesia~Exclusion Criteria:~* Preexisting sensory or motor deficit in operative extremity~* Patients with a contraindication to general anesthesia~* Patient undergoing meniscal or ligamentous repair

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Subarachnoid block (Type: EXPERIMENTAL): None
- General anesthesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ADHD/Me Bibliotherapy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* Meet ADHD criteria based on ADHD evaluation~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- ADH-Me Book (Type: EXPERIMENTAL): Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support.
- No ADH-Me Book (Type: SHAM_COMPARATOR): Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TRIGEN SURESHOT™ Distal Targeting System Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Unilateral femoral shaft fracture requiring intramedullary nailing in which the use of stereotactic surgery may be appropriate.~* Subject is between 18-80 years of age.~* Subject is skeletally mature~* Subject is of legal age and capable of providing legal consent.~* Subject is suitable for current Intramedullary Nailing procedure~* Subject willing to accept randomization either to the TRIGEN SURESHOT Distal Targeting System or TRIGEN standard instrumentation.~Exclusion Criteria~* Femur shaft fracture not amenable to intramedullary nailing in which the use of sterotactic surgery may be inappropriate.~* Fracture with vascular injury (Gustilo Type IIIC) requiring repair~* Open fractures where open wound is in communication with distal targeting holes and therefore would influence duration of locking procedure (i.e. potentially no need for incisions for locking screw placement).~* Fracture of the Metaphyseal distal femur with intraarticular comminution~* Known Pathological Fracture~* Subject is a prisoner~* Operative procedure for closed fracture is scheduled for greater than 2 weeks for closed fractures~* Subject has cognitive issue/mental status conditions that preclude intramedullary nailing in the judgment of the investigator.~* Contralateral femoral shaft fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TRIGEN SURESHOT Distal Targeting (Type: EXPERIMENTAL): TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
- Standard Nailing Instrumentation. (Type: ACTIVE_COMPARATOR): Free-hand technique utilizes x-rays to find screw holes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Image-derived Prediction of Response to Chemo-radiation in Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, primary supratentorial glioblastoma (WHO grade IV).~Exclusion Criteria:~* No informed consent can be obtained~* Inability to undergo MRI examination, due to metal implants, pacemaker etc.~* Not eligible for Stupp-regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard chemoradiotherapy (Type: None): Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CT Lucia 601 IOL Implantation in the Sulcus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with an implantation of a CT Lucia 601 lens for different reasons:~  * During vitrectomy to treat a complicated cataract surgery and had the implantation of a CT Lucia 601 IOL in the sulcus or patients~ * During phaco surgery with a posterior capsule tear that necessitated the implantation of the implant lens in the sulcus~ * Explantation of an in-the-bag lens and implantation of a CT Lucia 601 as replacement lens (e.g. to treat opacification of the implant lens or intolerance of the implant lens).~* Age : \> 18 years~* Signed informed consent~* Preoperative myopia less than 10 diopters~* Implantation of the CT Lucia IOL at least six months earlier~Exclusion Criteria:~* History of uveitis~* Ocular pathology or history that could influence the biometry of the effective lens position, such as ocular trauma with zonulolysis, congenital iris- or lens defects etc.~* Any eye condition influencing the lens position (to be specified) according to the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Two or more symptoms of acute appendicitis for at least 24 hours or radiologic evidence of complicated appendicitis~* Able to take medicine orally after recovering from surgery~* If female, using birth control~Exclusion Criteria:~* History of allergy to any study medication~* Life expectancy \< 72 hours~* APACHE II (health) score \> 25~* Neutropenic (low white blood cell count)~* HIV positive with current or past CD4 count \< 200/mm\^3~* Low platelet count (bleeds easily)~* Malnourished with low albumin~* Condition requiring use of major tranquilizers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomics of GLP1 Receptor Agonists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Member of the Old Order Amish community in Lancaster County, Pennsylvania~* BMI: 18-40 kg/sq.m.~Exclusion Criteria:~* Known allergy to exenatide~* History of diabetes, random glucose \>200 mg/dL, or HbA1c \> 6.5%~* Significant debilitating chronic cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judges will make interpretation of the results difficult or increase the risk of participation~* Seizure disorder~* Pregnant by self-report or known pregnancy within 3 months of the start of study~* Currently breast feeding or breast feeding within 3 months of the start of the study~* Estimated glomerular filtration rate \<60 mL/min/1.73m2~* Hematocrit \<35%~* Liver function tests greater than 2 times the upper limit of normal~* Abnormal TSH~* History of pancreatitis or pancreatic cancer. Personal or family history of medullary carcinoma of the thyroid.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Homozygous for major alleles of GCGR and GIPR (Type: OTHER): Based on data in a genotype database, these individuals were homozygous for the wild type major alleles of both GCGR and GIPR.
- Homozygous for missense variant in GIPR (Type: OTHER): Based on data in a genotype database, these individuals were homozygous for rs1800437 a missense variant (p.E354Q) in the GIP receptor gene (GIPR).
- Homozygous for missense variant in GCGR (Type: OTHER): Based on data in a genotype database, these individuals were homozygous for rs1801483a missense variant (p.G40S) in the glucagon receptor gene (GCGR).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: NewBreez Safety and Efficacy Evaluation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years old~2. Congenital or acquired, central or peripheral, neurological or neuromuscular disorder associated with laryngeal dysfunction with aspirations~3. Has a tracheotomy or tracheostomy and is indicated for use of a hood weaning kit~4. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: scanner, radiographic swallowing study, nasopharyngoscopy , NewBreez ILP implant as well as quality-of-life evaluation~5. Must be able to understand and be willing to provide written informed consent~Exclusion Criteria:~1. Any condition that precludes the insertion of the NewBreez ILP or ancillary implantation device~2. Major swallowing disorder~3. Existing coagulation disorder~4. Previous esophageal stenting~5. Life-expectancy \< 12 months~6. Be pregnant or breastfeeding or intention of becoming pregnant during the study (if female of childbearing potential)Point of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NewBreez ILP (Type: EXPERIMENTAL): Implantation of a NewBreez ILP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues